Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: J Immunol. 2019 Oct 25;203(11):2928–2943. doi: 10.4049/jimmunol.1900792

Figure 4. Comparison of NK and CD8+ T cell dynamics in RM treated with anti-IL-15 during primary SIV infection.

Figure 4.

(A) Absolute NK cell counts, including CD16+ CD56−, CD16− CD56+ and CD16− CD56− subsets in the blood after primary SIVmac239 infection and short duration anti-IL-15 mAb (Group A, n = 7), long duration anti-IL-15 mAb (Group B, n = 8) or IgG control mAb (Group C, n = 8) treatment. Results (mean + SEM) are shown as percentage of baseline. (B) RM received three i.v. doses of BrdU at 30 mg/kg over 24 hours between days 40 and 41 pi. Lymphocytes were isolated from the blood or tissues and further analyzed for T cell markers and BrdU positivity. Figure shows comparison of CD8+ TCM, TTrM, TEM and TN dynamics (absolute counts, proliferative fraction and BrdU decay) in blood after primary SIVmac239 infection and short duration anti-IL-15 mAb (Group A, n = 7), long duration anti-IL-15 mAb (Group B, n = 8) or IgG control mAb (Group C, n = 8) treatment. Results (mean + SEM) are shown as absolute counts percentage of baseline or percentage of Ki-67+, change (Δ) from baseline or percentage of BrdU+, change from peak. Significance of difference in all parameters was assessed as described in Materials and Methods (*p < 0.05).